Business Wire

Credorax Launches Cutting-edge Chargeback Prevention Solution

20.7.2021 14:13:00 EEST | Business Wire | Press release

Share

Leading smart payments provider and merchant acquiring bank, Credorax, has announced it is upping the ante in the world of fraud protection and chargeback mitigation by launching a cutting-edge solution to preventing chargebacks.

Credorax’s Chargeback PREVENTION marks a landmark partnership with Ethoca (owned by Mastercard), the leading, global provider of collaboration-based technology, and Verifi (a Visa solution), the leading provider of transaction risk management services for card-not-present merchants.

Merchants can now take control of their chargebacks by preventing chargebacks before they are initiated. Credorax’s innovative service offers merchants the ability to create rules that automate refunds or issue a manual refund after receiving an alert – both stop disputes from escalating to chargebacks.

Chargeback PREVENTION is part of the Credorax Risk Management suite and protects merchants from fraud and chargebacks through every stage of the transaction lifecycle. Credorax’s unique solution seamlessly combines the ingenuity of machine learning intelligence and intuitive data analysis to continually improve its fraud detection algorithm. It can accurately detect legitimate and fraudulent transactions on a large scale.

Depending on individual merchant needs and risk preferences, thresholds and rules management can be changed as and when necessary, tailored to the merchant’s unique requirements. Credorax also provides dedicated training to help merchants become familiar with Credorax’s fraud and chargeback prevention tools and optimise them based on a merchant’s particular specifications.

Drawing upon data from the world’s biggest ecommerce brands, banks, and payments providers, with Credorax’s Chargeback PREVENTION, merchants can view dashboards where they can monitor transactions, specific transaction rules and view alerts, giving them a complete overview their transaction lifecycles.

Moshe Selfin, Chief Technology Officer for Credorax, commented: “Ecommerce is booming, which means fraud and chargebacks rates are also accelerating – shockingly, merchant losses to friendly fraud were estimated to amount to over $50 billion in 2020. While far from ideal, the current state of play is undoubtedly driving levels of innovation and solution like we’ve never seen before. The sheer demand for turnkey, preventative fraud management systems, like ours, coupled with the advances in AI and real-time detection has the ability to put merchants on the front foot when dealing with fraudsters – a position they’ve never really been in before.

“With access to broadest possible range of bank issuer coverage globally, merchants have never been in a stronger position to armour themselves against the high costs and reputational hits that come with such attacks.”

Credorax is a full-service payments processor and acquirer dedicated to helping merchants by using cutting-edge technology and insights to bring innovative solutions to the market. Its payment experts are available to explain in more detail how you can benefit from its chargeback management and representation services.

Moshe added: “Our vision at Credorax has always been to provide merchants with the technology they need to take advantage of the global opportunities available to them. All while being safe in the knowledge that there are proactive and preventative measures in place that will make cross-border trading a pleasure and not a pressure.

“With a robust onboarding process that allows for an ongoing customer management journey with our specialist teams all over the world and a deep understanding of the nuances of payment processing, this is an exciting milestone in our ambition to further enhance Credorax’s exciting suite of offerings.”

For more information about Credorax’s Chargeback Prevention, visit: https://learn.credorax.com/contact-us .

#ENDS#

About Credorax

Credorax is a smart payments provider and fully licensed bank providing cross-border processing for eCommerce and omni-channel payments. Our core gateway technology, SourceTM, has been developed in-house to provide a streamlined payments experience so smart, that merchants can reach their full business potential simply by better managing their payments. Credorax merchants can accept more than a hundred cards and local payment methods and get paid in their currency of choice. Our merchants also enjoy best-in-class approval rate optimisation, advanced fraud protection, business intelligence and a host of other value-added services and products adding up to a payments experience unlike any other.

To learn more, contact us at grow@credorax.com or visit www.credorax.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Press Contact Credorax
Marisa Rijpkema
Head of Marketing, Credorax
Marisa.rijpkema@credorax.com
+31-6-42140533

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 02:56:00 EEST | Press release

Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting

FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release

Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co

Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release

Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border

Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release

For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro

Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release

Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye